title: Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
abstract: The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies. The Dutch Colorectal Cancer Group (DCCG) is a national multidisciplinary clinical research group in The Netherlands. The 3 CAIRO studies of the DCCG address clinically relevant questions in patients with advanced colorectal cancer: the benefit of combination versus sequential therapy, targeting vascular endothelial growth factor and epidermal growth factor receptor, and the role of maintenance therapy. This article presents the outline of these studies and summarizes the current results.
authors.affiliation: Department of Medical Oncology, Radboud University Nijmegen Medical Center, The Netherlands.
authors.forename: Lieke
authors.initials: L
authors.lastname: Simkens
authors.forename: Jolien
authors.initials: J
authors.lastname: Tol
authors.forename: Miriam
authors.initials: M
authors.lastname: Koopman
authors.forename: Linda
authors.initials: L
authors.lastname: Mol
authors.forename: Ninja
authors.initials: N
authors.lastname: Antonini
authors.forename: Hans
authors.initials: H
authors.lastname: van Krieken
authors.forename: Cornelis
authors.initials: C
authors.lastname: Punt
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000187:drug effects; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D009367:Neoplasm Staging; D009426:Netherlands; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; D000068818:Cetuximab; D005472:Fluorouracil